Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Larry Johnson

TitleProfessor
InstitutionUniversity of Arkansas for Medical Sciences
DepartmentInternal Med, College of Medicine
Address3S 14 Shorey
324 UAMS Campus Dr.
Mail Slot # 555
Little Rock AR 72205
Phone501-686-5525
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    002928Y121     (BERLINSKI, ARIEL)Apr 1, 2023 - Jun 30, 2024
    Cystic Fibrosis Foundation
    Cystic Fibrosis Foundation Therapeutics Developmen-Renewal
    Role: Principal Investigator
    BMX     (JOHNSON, LARRY G)Nov 8, 2022 - Nov 7, 2032
    BiomX, Inc. - Pass Through: Labcorp Drug Development Inc.
    A Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Nebulized Bacteriophage Treatment in Outpatient Adult Cystic Fibrosis (CF) Subjects with Chronic Pseudomonas aeruginosa (PsA) Pulmonary Infection (IRB 273998)
    Role: Principal Investigator
    BMX-04-001     (JOHNSON, LARRY G)Nov 8, 2022 - Nov 7, 2032
    BiomX, Inc. - Pass Through: Labcorp Drug Development Inc.
    A Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Nebulized Bacteriophage Treatment in Outpatient Adult Cystic Fibrosis (CF) Subjects with Chronic Pseudomonas aeruginosa (PsA) Pulmonary Infection (IRB 273998)
    Role: Principal Investigator
    VX20     (JOHNSON, LARRY G)Oct 4, 2022 - Oct 3, 2032
    Vertex Pharmaceuticals, Inc.
    A Phase 3, Open-Label Study Evaluating the Long-Term Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis (IRB 274469)
    Role: Principal Investigator
    VX20-121-104     (JOHNSON, LARRY G)Oct 4, 2022 - Oct 3, 2032
    Vertex Pharmaceuticals, Inc.
    A Phase 3, Open-Label Study Evaluating the Long-Term Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis (IRB 274469)
    Role: Principal Investigator
    JOHNSO22Y0     (BERLINSKI, ARIEL)Apr 1, 2022 - Mar 31, 2023
    Cystic Fibrosis Foundation
    Cystic Fibrosis Foundation Therapeutics Development Center
    Role: Principal Investigator
    12722SUB     (JOHNSON, LARRY G)Jan 24, 2022 - Jan 23, 2032
    Cystic Fibrosis Foundation - Pass Through: Seattle Children's Hospital d/b/a Seattle Children's Research Institute
    A Prospective Study Evaluating Maternal and FetaL Outcomes in the ERa of ModulatorS (MAYFLOWERS) (IRB 263120)
    Role: Principal Investigator
    CC037-AD     (JOHNSON, LARRY G)Jul 1, 2021 - Jun 30, 2024
    Cystic Fibrosis Foundation
    CFF Care Center Award 2021_2022
    Role: Principal Investigator
    ANDERS14Y0     (BERLINSKI, ARIEL)Apr 1, 2021 - Mar 31, 2022
    Cystic Fibrosis Foundation
    CFT Therapeutic Development Center Renewal 2021
    Role: Principal Investigator
    JBT101-LTS     (JOHNSON, LARRY G)Feb 12, 2021 - Feb 11, 2022
    Corbus Pharmaceuticals Holdings, Inc.
    AN OBSERVATIONAL LONG-TERM SAFETY SURVEILLANCE STUDY OF PARTICIPANTS FROM CORBUS SPONSORED LENABASUM PIVOTAL CLINICAL TRIALS (IRB 261101)
    Role: Principal Investigator
    JBT101-LTS-001     (JOHNSON, LARRY G)Feb 12, 2021 - Feb 11, 2022
    Corbus Pharmaceuticals Holdings, Inc.
    AN OBSERVATIONAL LONG-TERM SAFETY SURVEILLANCE STUDY OF PARTICIPANTS FROM CORBUS SPONSORED LENABASUM PIVOTAL CLINICAL TRIALS (IRB 261101)
    Role: Principal Investigator
    CX     (JOHNSON, LARRY G)Aug 18, 2020 - Aug 13, 2030
    Calithera Biosciences, Inc. - Pass Through: Rho, Inc
    No FP attached
    Role: Principal Investigator
    CX-280-202     (JOHNSON, LARRY G)Aug 18, 2020 - Aug 13, 2030
    Calithera Biosciences, Inc. - Pass Through: Rho, Inc
    No FP attached
    Role: Principal Investigator
    ABBV     (JOHNSON, LARRY G)Jul 7, 2020 - Jul 30, 2030
    AbbVie Inc
    No FP attached
    Role: Principal Investigator
    ABBV-2222     (JOHNSON, LARRY G)Jul 7, 2020 - Jul 30, 2030
    AbbVie Inc
    No FP attached
    Role: Principal Investigator
    PROMISE-OB     (JOHNSON, LARRY G)May 8, 2019 - Jun 2, 2029
    Cystic Fibrosis Foundation - Pass Through: Seattle Children's Hospital d/b/a Seattle Children's Research Institute
    No FP attached
    Role: Principal Investigator
    PROMISE-OB-18     (JOHNSON, LARRY G)May 8, 2019 - Jun 2, 2029
    Cystic Fibrosis Foundation - Pass Through: Seattle Children's Hospital d/b/a Seattle Children's Research Institute
    No FP attached
    Role: Principal Investigator
    VX17     (JOHNSON, LARRY G)Oct 1, 2018 - Oct 9, 2028
    Vertex Pharmaceuticals, Inc.
    No FP attached
    Role: Principal Investigator
    VX17-445-105     (JOHNSON, LARRY G)Oct 1, 2018 - Oct 9, 2028
    Vertex Pharmaceuticals, Inc.
    No FP attached
    Role: Principal Investigator
    CMHC211     (JOHNSON, LARRY G)Sep 1, 2018 - Aug 31, 2021
    Cystic Fibrosis Foundation
    Mental Health Coordinator Position - Continuation
    Role: Principal Investigator
    CMHC211-18     (JOHNSON, LARRY G)Sep 1, 2018 - Aug 31, 2021
    Cystic Fibrosis Foundation
    Mental Health Coordinator Position - Continuation
    Role: Principal Investigator
    CMHC2111     (JOHNSON, LARRY G)Sep 1, 2018 - Aug 31, 2021
    Cystic Fibrosis Foundation
    Mental Health Coordinator Position - Continuation
    Role: Principal Investigator
    VX17-445-103     (JOHNSON, LARRY G)Aug 10, 2018
    Vertex Pharmaceuticals, Inc.
    No FP attached
    Role: Principal Investigator
    VX17-445-102     (JOHNSON, LARRY)Jun 26, 2018
    Vertex Pharmaceuticals, Inc.
    A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
    Role: Principal Investigator
    JBT101-CF     (JOHNSON, LARRY)Apr 19, 2018
    Corbus Pharmaceuticals Holdings, Inc.
    A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis
    Role: Principal Investigator
    JBT101-CF-002     (JOHNSON, LARRY)Apr 19, 2018
    Corbus Pharmaceuticals Holdings, Inc.
    A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis
    Role: Principal Investigator
    CHEC-OB     (JOHNSON, LARRY G)Feb 23, 2018 - Feb 22, 2028
    Cystic Fibrosis Foundation Therapeutics, Inc. - Pass Through: Seattle Children's Hospital d/b/a Seattle Children's Research Institute
    No FP attached
    Role: Principal Investigator
    CHEC-OB-17     (JOHNSON, LARRY G)Feb 23, 2018 - Feb 22, 2028
    Cystic Fibrosis Foundation Therapeutics, Inc. - Pass Through: Seattle Children's Hospital d/b/a Seattle Children's Research Institute
    No FP attached
    Role: Principal Investigator
    VX16     (JOHNSON, LARRY)Aug 29, 2017
    Vertex Pharmaceuticals, Inc.
    A Phase 1/2 Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis
    Role: Principal Investigator
    VX16-445-001     (JOHNSON, LARRY G)Aug 29, 2017
    Vertex Pharmaceuticals, Inc.
    A Phase 1/2 Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis
    Role: Principal Investigator
    GLPG2222-CL     (JOHNSON, LARRY)Jul 5, 2017
    Quintiles Transnational Corporation
    A Phase IIa, randomized, double-blind, placebo-controlled study to evaluate multiple doses of GLPG2222 in subjects with Cystic Fibrosis who are homozygous for the F508del mutation
    Role: Principal Investigator
    GLPG2222-CL-202     (JOHNSON, LARRY)Jul 5, 2017
    Quintiles Transnational Corporation
    A Phase IIa, randomized, double-blind, placebo-controlled study to evaluate multiple doses of GLPG2222 in subjects with Cystic Fibrosis who are homozygous for the F508del mutation
    Role: Principal Investigator
    CC037     (JOHNSON, LARRY)Jul 1, 2017 - Jun 30, 2021
    Cystic Fibrosis Foundation
    Cystic Fibrosis Care Centers - 2017-2018
    Role: Principal Investigator
    CC037-17AD     (JOHNSON, LARRY)Jul 1, 2017 - Jun 30, 2021
    Cystic Fibrosis Foundation
    Cystic Fibrosis Care Centers - 2017-2018
    Role: Principal Investigator
    ANDERS14YO     (JOHNSON, LARRY G)Jan 1, 2017 - Mar 31, 2021
    Cystic Fibrosis Foundation
    CFT Therapeutic Development Center Renewal 2018 - Continuation - Continuation
    Role: Principal Investigator
    JBT     (JOHNSON, LARRY G)Dec 17, 2016
    Corbus Pharmaceuticals Holdings, Inc.
    A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Cystic Fibrosis
    Role: Principal Investigator
    JBT-101 Cystic Fibrosis     (JOHNSON, LARRY)Dec 17, 2016
    Corbus Pharmaceuticals Holdings, Inc.
    A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Cystic Fibrosis
    Role: Principal Investigator
    CCRX211     (JOHNSON, LARRY)Nov 1, 2016 - Oct 31, 2019
    Cystic Fibrosis Foundation
    CFF Implementation of OP Clinical Pharm Services: Pharm Tech Award
    Role: Principal Investigator
    CCRX211-16     (JOHNSON, LARRY G)Nov 1, 2016 - Oct 31, 2019
    Cystic Fibrosis Foundation
    CFF Implementation of OP Clinical Pharm Services: Pharm Tech Award - Continuation - Continuation
    Role: Principal Investigator
    Advance Account     (HENRY-TILLMAN, RONDA S)Jul 28, 2016 - Jun 30, 2018
    Arkansas Department of Health
    Colorectal Cancer Screening Program- Resubmission
    Role: Principal Investigator
    CC037-16AD     (JOHNSON, LARRY G)Jul 1, 2016 - Jun 30, 2017
    Cystic Fibrosis Foundation
    CFF Accreditation and Funding 2016/2017
    Role: Principal Investigator
    VX14     (JOHNSON, LARRY G)Mar 22, 2016 - Jul 21, 2016
    Vertex Pharmaceuticals, Inc.
    VX-661 205310
    Role: Principal Investigator
    VX14-661-108      (JOHNSON, LARRY)Mar 22, 2016 - Jul 21, 2016
    Vertex Pharmaceuticals, Inc.
    VX-661 205310
    Role: Principal Investigator
    VX14-661-108     (JOHNSON, LARRY)Mar 22, 2016 - Jul 21, 2016
    Vertex Pharmaceuticals, Inc.
    VX-661 205310
    Role: Principal Investigator
    CC037-15AD     (JOHNSON, LARRY)Jul 1, 2015 - Jun 30, 2016
    Cystic Fibrosis Foundation
    CFF Renewal 2015-2016
    Role: Principal Investigator
    CFF#ANDERS14Y0     (JOHNSON, LARRY G)Jan 1, 2015 - Dec 31, 2015
    Cystic Fibrosis Foundation
    CFFT Therapeutics Dev Center Renewal 2014
    Role: Principal Investigator
    PAH QuERI     (JOHNSON, LARRY G)Apr 26, 2012 - Apr 25, 2014
    Actelion
    Pulmonary Arterial Hypertension (PAH) Quality Enhancement Research Initiative (QuERI) Extension Program
    Role: Principal Investigator
    PAHQuERI     (JOHNSON, LARRY)Apr 26, 2012 - Apr 25, 2014
    Actelion
    Pulmonary Arterial Hypertension (PAH) Quality Enhancement Research Initiative (QuERI) Extension Program
    Role: Principal Investigator
    CSA Protocol PIPF-012     (JOHNSON, LARRY)Jun 17, 2008
    InterMune, Inc.
    An Open-Label Extension Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF) Who Complete the CAPACITY St
    Role: Principal Investigator
    CSAProtocolPIPF     (JOHNSON, LARRY G)Jun 17, 2008
    InterMune, Inc.
    An Open-Label Extension Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF) Who Complete the CAPACITY St
    Role: Principal Investigator
    0555409U     (JOHNSON, LARRY)Jul 1, 2005 - Dec 31, 2006
    American Heart Association (Mid-Atlantic Affiliate)
    Gene Transfer Strategies for Pulmonary Hypertension
    Role: Principal Investigator
    JOHNO05P0     (JOHNSON, LARRY G)Jul 1, 2005 - Dec 31, 2006
    Cystic Fibrosis Foundation
    Airway Tight Junctions, Permeability, and Inflammation
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions. Don't see publications published under other names? Login to add alternative names.
    List All   |   Timeline
    1. Johnson, L. G., Gubrij I.B., Martin S.R., Pangle A.K., Kurten R. Inconsistent attentuation of monocrotaline-induced pulmonary hypertension in rats by luminal delivery of AAV pseudotyped prostacyclin synthase vectors. Human Gene Therapy. 2013.
    2. Johnson, L. G., Gubrij, I.B., Pangle, A.K., Pang, L. MicroRNAs as potential targets for therapy of pulmonary hypertension. 2013; S169.
    3. Johnson, L. G., Gubrij, I.B., Pangle, A.K., Pang,L. Upregulation of microRNAs 21and 223 in an animal model of Pulmonary Hypertension. 2013; A4644.
    4. Sasieta-Tello, H.C., Bhaskar, N, McKee, S, Johnson, L. G. Diffuse Alveolar Hemorrhage Related To Pomalidomide. 2013; A5041.
    5. Johnson, L. G., Badireddi S. Approach to diagnosis and management of patients with pulmonary hypertension. Arkansas Med Journal. 2013.
    6. Martin SR, Johnson, L. G. Geriatric Rehabilitation: Rehabilitation Medicine Quick Reference (RMQR) Series. Normal Age Related Pulmonary Changes. 2013.
    7. Johnson, L. G., Bhaskar N, Jagana R. Non tuberculous Empyema Necessitatis in patient with AML. Am J Respir Crit Care Med. 2013.
    8. Johnson L. Gene and Cell Therapy: Therapeutic Mechanisms and Strategies. Progress Toward Gene Therapy for Cystic Fibrosis. 2009.
    9. Johnson, L. G. Gene and Cell Therapy: Therapeutic Mechanisms and Strategies. Progress Toward Gene Therapy for Cystic Fibrosis. 2008.
    10. Martin, S.R., M. Gabor, M. Al-Hamed, R.S. Everett, Johnson, L. G. Attenuation of Pulmonary Hypertension in Animal Models by AAV Gene Transfer of Prostacyclin Synthase. 2008; 177:A261.
    11. Everett, R.S., Johnson, L. G. Correlation between lung inflammation and barrier function. Ped. Pulmonol Suppl. 2007; 30:263.
    12. McKay, T., M. Patel, R.J. Pickles, Johnson, L. G., J.C. Olsen. Influenza M2 envelope protein augments avian influenza hemagglutinin pseudotyping of lentiviral vectors. Gene Ther. 2006; in press.
    13. Everett, R.S., Johnson, L. G. Role of claudin-7 in airway epithelial function. 2006; Suppl. 29:241-242.
    14. Johnson, L. G. Applications of imaging techniques to studies of epithelial tight junctions. Adv. Drug Deliv. Rev. 2005; 57(1):111-121.
    15. Everett, R.S., W. Feng, M.K. Vanhook, Johnson, L. G. Specific modulation of airway tight junctions by claudin peptides. 2005; Suppl. 28:271.
    16. Olsen, John C, Tristan McKay, Angela M. Giddings, Lawrence E. Ostrowski, Raymond J. Pickles, Johnson, L. G. Species-specific differences in airway gene transfer efficiency mediated by an equine lentivirus vector. 2005; Suppl. 28:282.
    17. Everett, R.S., M.K. Vanhook, I. Toth, Johnson, L. G. Specific modulation of tight junctions to enhance airway gene transfer. 2005; 11:S140-141.
    18. Everett, R.S., M.K. Vanhook, W. Feng, Johnson, L. G. Strategies for detection of molecular mechanisms of cytokine-induced changes in anion conductance in airway epithelial tight junctions. 2004; Suppl. 27:243.
    19. Johnson, L. G., M. Patel, M.K. Vanhook, J.C. Olsen. Gene Transfer Strategies for Pulmonary Hypertension. 2004; 9:S191.
    20. Coyne, C.B., C.M.P. Ribeiro, R.C. Boucher, Johnson, L. G. Acute mechanism of medium chain fatty acid-induced enhancement of airway epithelial permeability. J. Pharmacol. Exp. Ther. 2003; 305(2):440-450.
    21. Coyne, C.B., T.L. Gambling, R.C. Boucher, J.L. Carson, Johnson, L. G. Role of claudin interactions in airway tight junctional permeability. Am. J. Physiol. Lung Cell Mol. Physiol. 2003; 285:L1166-L1178.
    22. Olsen, J.C., M. Patel, T.R. McKay, A.M. Giddings, M.K. Vanhook, Johnson, L. G. Hybrid influenza/lentiviral vectors for gene transfer to the polarized epithelia. 2003; 7(5):S29.
    23. Coyne, C.B, W. Feng, A.D. Betensley, M.K. Vanhook, Johnson, L. G. Targeted disruption of epithelial tight junctions. 2003; Suppl. 25:243-244.
    24. Coakley, R.D., B.R. Grubb, A.M. Paradiso, J.T. Gatzy, Johnson, L. G., R.C. Boucher. Abnormal surface liquid pH regulation by cultured cystic fibrosis bronchial epithelium. Proc. Natl Acad. Sci 100(26). 2003; 16083-16088.
    25. Johnson, L. G., M.K. Vanhook, C.B. Coyne, N. Haykal-Coates, S.H. Gavett. Safety and efficiency of modulating paracellular permeability to enhance airway epithelial gene transfer in vivo. Human Gene Ther. 2003; 14(8):729-747.
    26. Coyne, C.B., R.C. Boucher, Johnson, L. G. Patterns of claudin gene expression in cystic fibrosis. 2002; Suppl. 24:246.
    27. Olsen, J.C., M. Patel, M.K. Vanhook, Johnson, L. G. Hybrid influenza/lentiviral vectors for gene transfer to the airways. 2002; Supp. 24:251.
    28. Coyne, C.B., Johnson, L. G. Role of claudins in airway tight junctions. 2002; 13:497a(supplement).
    29. Johnson, L. G., M.K. Vanhook, W. O’Neal. Persistence of transgene expression mediated by a helper dependent adenoviral vector in murine airways. 2002; 5(5):S348.
    30. Coyne, C.B., R.C. Boucher, Johnson, L. G. Patterns of claudin gene expression in cystic fibrosis. 2002; Suppl. 24:246.
    31. Coyne, C.B., M.K. Vanhook, T.L. Gambling, J.L. Carson, R.C.Boucher, Johnson, L. G. Regulation of airway tight junctions by proinflammatory cytokines. Mol. Biol. Cell. 2002; 13:3218-3234.
    32. Coyne, C.B., M.K. Vanhook, R.D. Coakley, R.C. Boucher, Johnson, L. G. Cytokine regulation of airway tight junctions. 2001; Suppl. 22: 234-235.
    33. Coyne, C.B., Johnson, L. G. Characterization of Human Airway Tight Junctions. 2001; 12:219a.
    34. Coyne, C.B., M.K. Vanhook, R.C. Boucher, Johnson, L. G. Safety and efficiency of medium chain fatty acid-induced enhancement of airway epithelia gene transfer. 2001; 3(5):S89.
    35. Coyne, C.B., M.M. Kelly, R.C. Boucher, Johnson, L. G. Enhanced epithelial gene transfer by modulation of tight junctions with sodium caprate. Am. J. Respir. Cell Mol. Biol. 2000; 23:602-609.
    36. Johnson, L. G., J.C. Olsen, L. Naldini, R.C. Boucher. Pseudotyped human lentiviral vector-mediated gene transfer to airway epithelia in vivo. Gene Ther. 2000; 7(7):568-574.
    37. Coyne, C.B., M.M. Kelly, C. Ribeiro, R.C. Boucher, Johnson, L. G. Mechanism and toxicity of medium chain fatty acid-induced enhancement of airway epithelial gene transfer in vitro. 2000; Suppl. 20:229.
    38. Olsen, J.C., M. Patel, J.B. Rohll, K.A. Mitrophanous, S. Yoon, F.J. Wilkes, S.M. Kingsman, A.J. Kingsman, K.A. Morse, M.M. Kelly, Johnson, L. G. Mol. Ther. 2000; 1(5): S315.
    39. Coyne, C.B., M.M. Kelly, C. Ribeiro, Johnson, L. G. Enhancement of airway epithelial gene transfer by medium chain fatty acids. 2000; 1(5): S77.
    40. Noone, P.G., K.W. Hohneker, Z. Zhou, C. Foy, C. Gipson, Johnson, L. G., K. Jones, T.L. Noah, M.W. Leigh, C. Schwartzbach, J. Efthimiou, R. Pearlman, R.C. Boucher, M.R. Knowles. Safety and biological efficacy of a lipid-CFTR complex for gene transfer in the nasal epithlium of adult patients with cystic fibrosis. Molecular Therapy. 2000; 1:105-114.
    41. Johnson, L. G., L. Naldini, J.C. Olsen, R.C. Boucher. VSV-G Pseudotyped human lentiviral vector-mediated gene transfer to airway epithelia. 1999.
    42. Olsen, J.C., J. Sechelski, Johnson, L. G. Equine infectious anemia vector-mediated gene transfer to polarized airway epithelia. 1999.
    43. Coyne, C.B., R.C. Boucher, Johnson, L. G. Systematic evaluation of intercellular junctional regulation to enhance gene transfer to airway epithelium. 1999; suppl. 19:258.
    44. Pickles, R.J., Johnson, L. G., J.C. Olsen, R. Gerard, D. Segal, R.C. Boucher. Correction of the CF bioelectrical defect in human CF well differentiated airway epithelial cells by re-targeting adenoviral vectors to lumenal P2Y2 purinoreceptors. 1999; suppl. 19:222.
    45. Olsen, J.C., M. Kelly, M. Patel, Johnson, L. G. Gene delivery to murine trachea by an equine lentiviral vector. 1999; suppl. 19:222.
    46. Johnson, L. G., M.M. Kelly, H. Ni, R.C. Boucher. Enhanced in vitro and in vivo ad-mediated gene transfer to airway epithelia by modulation of paracellular permeability. 1999; suppl. 19:225.
    47. Parsons, D.W., B. Grubb, Johnson, L. G., R.C. Boucher. Enhancement of in vivo adenoviral gene transfer via modification of host barrier properties with a surface active agent. Human Gene Ther. 1998; 9:2661-2672.
    48. Knowles, M.R., P.G. Noone, K. Hohneker, Johnson, L. G., R.C. Boucher. A double-blind, placebo controlled, dose ranging study to evaluate the safety and biological efficacy of the lipid-DNA complex GR213487B in the nasal epithelium of adult patients with cystic fibrosis. Human Gene Ther. 1998; 9:249-269.
    49. Johnson, L. G., J.P. Mewshaw, R.C. Boucher, J.C. Olsen. In vivo airway gene transfer using pseudotyped retroviral vectors. 1998; 157(3):A480.
    50. Johnson, L. G., R.C. Boucher. Enhancement of adenovirus-mediated gene transfer to airway epithelia by modulation of tight junctional permeability. 1998; suppl. 17, p281-282.
    51. Knowles, M.R, P.G. Noone, K. Hohneker, Johnson, L. G., R.C. Boucher. A double-blind, placebo controlled, dose ranging study to evaluate the safety and biological efficacy of the lipid-DNA complex GR213487B in the nasal epithelium of adult patients with cystic fibrosis. Human Gene Ther. 1998; 9:249-269.
    52. Johnson, L. G., J.P. Mewshaw, T. Friedman, R.C. Boucher, J.C. Olsen. Effect of host modification and age on airway epithelial gene transfer mediated by a murine leukemia virus-derived vector. J. Virol. 1998; 72:8861-8872.
    53. Pickles, R.J., S.M. Kreda, J. Olsen, Johnson, L. G., R. Gerard, D. Segal, R.C. Boucher. High efficiency gene transfer to polarised epithelial cells by re-targeting adenoviral vectors to P2Y2 purinergic receptors with bi-specific antibodies. 1998; suppl. 17, p261.
    54. Black, H.R., J.R. Yankaskas, Johnson, L. G., T.L. Noah. Interleukin-8 and interleukin-10 production by cystic fibrosis nasal epithelial cells after tumor necrosis factor-? and respiratory syncytial virus stimulation. Am. J. Respir. Cell Mol. Biol. 1998; 19:210-215.
    55. Johnson, L. G. Gene therapy for lung disease: part two RT. 1997; 10(1):73-75.
    56. Johnson, L. G., R.C. Boucher. Toward correction of the genetic defect in cystic fibrosis. In: Lung Biology in Health and Disease: Gene Therapy for Diseases of the Lung. 1997.
    57. Parsons, D.W., C.S. Freiberg, B.R. Grubb, Johnson, L. G., R.C. Boucher. Efficiency of in-vivo gene transfer in murine nasal airway: modulation by detergent pretreatment and airway disease. 1997; suppl. 14, p.260.
    58. Johnson, L. G., J.P. Mewshaw, R.C. Boucher, J.C. Olsen. Improved in vivo gene transfer to murine airway epithelia using pseudotyped retroviral vectors. 1997; suppl. 14, p. 279.
    59. Gabriel, S.E., E.L. Briley, A. Sannuti, Johnson, L. G., J.C. Olsen, R.C. Boucher. Candidate genes for Ca2+-activated Cl- channels identified by differential display of normal and CF airway epithelial cells. 1997; suppl. 14, p. 237.
    60. Johnson, L. G., J.P. Mewshaw, Luigi Naldini, J.C. Olsen, R.C. Boucher. Assessment of airway gene transfer using a VSV-G pseudotyped lentiviral vector. 1997; suppl. 14, p. 257.
    61. Black, H.R., J.R. Yankaskas, Johnson, L. G., T.L. Noah. Interleukin-8 and interleukin-10 production by cystic fibrosis nasal epithelial cells after tumor necrosis factor-? and respiratory syncytial virus stimulation. 1997; suppl. 14, p.315.
    62. Matsui, H., S. Randell, Johnson, L. G., R.C. Boucher. Loss of binding and entry of liposome-DNA complexes decreases transfection efficiency in differentiated rat tracheal epithelial cells. J.Biol.Chem. 1997; 272(2):1117-1126.
    63. Johnson, L. G., R.J. Pickles, S.E. Boyles, J.C. Morris, J.C. Olsen, R.C. Boucher, Z. Zhou, H. Ye. In vitro assessment of variables affecting the efficiency and efficacy of adenovirus-mediated gene transfer to cystic fibrosis airway epithelia. Human Gene Therapy. 1996; 7:51-59.
    64. Johnson, L. G., J.C. Morris, S.E. Boyles, R.C. Boucher, J.C. Olsen. In vivo airway gene transfer and in vitro correction of CF airway cells without selection by a VSV-G pseudotyped retroviral vector. 1996; suppl. 13, p. 278.
    65. Hart, P.J., J.C. Olsen, Johnson, L. G., R.J. Pickles, S. Randell, R.C. Boucher. Reduced retroviral entry into polarized airway epithelia. 1996; suppl. 13, p. 278.
    66. Johnson, L. G. A perspective on gene therapy for cystic fibrosis. Expert Opinion on Invest. Drugs. 1996; 5(1):29-42.
    67. Parsons, D., Johnson, L. G., J. Morris, S. Boyles, R. Boucher. Enhancement of in vivo gene transfer in murine nasal epithelium by synthetic detergent injury. 1996; suppl. 13, p. 271.
    68. Cheng, P.W., Johnson, L. G. Restoration of chloride transport properties in CFT1 cells by insulin-facilitated gene transfer. 1996; 153:A114.
    69. Johnson, L. G., J.C. Morris, T. Friedmann, J.C. Olsen, R.C. Boucher. In vitro and in vivo retrovirus-mediated gene transfer to airway epithelia using a VSV-G pseudotyped vector. 1995; suppl. 12, p. 230.
    70. Johnson, L. G. Gene therapy for cystic fibrosis. Chest 107(2). 1995; 77S-83S.
    71. Knowles, M.R., K. Hohneker, Z. Zhou, J.C. Olsen, T.L. Noah, P.-C. Hu, M.W. Leigh, J. Engelhardt, L.J. Edwards, K. Jones, M. Grossman, J.M. Wilson, Johnson, L. G., R.C. Boucher. A controlled study of adenoviral vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. N. Engl. J. Med. 1995; 333:823-831.
    72. Teramoto, S., Johnson, L. G., W. Huang, M.W. Leigh, R.C. Boucher. Effect of adenoviral vector infection on cell proliferation in a cultured primary human airway epithelial cells. Human Gene Ther. 1995; 6:1045-1053.
    73. Matsui, H., Johnson, L. G., R.C. Boucher. Cationic liposomal entry into dedifferentiated and redifferentiated airway cells. 1995; suppl. 12, p. 220.
    74. Teramoto, S., Johnson, L. G., M.W. Leigh, R.C. Boucher. Influences of LPS on adenovirus (Ad)-mediated gene transfer to cultured human airway cells and adenoviral vector-induced apoptosis. 1995; suppl. 12, p. 227.
    75. Johnson, L. G., S.E. Boyles, J. Wilson, R.C. Boucher. Normalization of raised sodium absorption and raised calcium-mediated chloride secretion by adenovirus-mediated expression of CFTR in primary human cystic fibrosis airway epithelial cells. J. Clin. Invest. 1995; 95:1377-1382.
    76. Pier, G.B, M. Grout, T.S. Zaidi, J.C. Olsen, Johnson, L. G., J.R. Yankaskas, J.B. Goldberg. Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to chronic lung infections. Science. 1995; 271:64-67.
    77. Mylett, J., Johnson, L. G., M.R. Knowles. Alternate Therapies for Cystic Fibrosis. Seminars in Respiratory Medicine 15(5). 1994; 426-433.
    78. Johnson, L. G., S.E. Boyles, W-H. Huang, R.C. Boucher. Efficiency of cationic liposome-mediated gene transfer to airway epithelia in vitro. 1994; suppl. 10, p.228.
    79. Olsen, J., W-H. Huang, Johnson, L. G., R.C. Boucher. Persistence of adenoviral vector gene expression in CF airway cells is due to integration of vector sequences into chromosomal DNA. 1994; suppl. 10, p. 230.
    80. Thomas, D., J. Mylett, M. Leigh, A. Jonczyk, J. Wilson, R. Boucher, Johnson, L. G. Analysis of pulmonary immunologic responses in mice to adenoviral gene transfer vector. 1994; suppl. 10, p. 234.
    81. Boucher, R.C, M.R. Knowles, Johnson, L. G., R. Pickles, J.C. Olsen, J.M. Wilson, J. Engelhardt, Y. Yang, M. Grossman. Gene therapy for cystic fibrosis using E1-deleted adenovirus: A phase I trial in the nasal cavity. Human Gene Therapy 5. 1994; 615-639.
    82. Teramoto, S., Johnson, L. G., W. Huang, M.W. Leigh, R.C. Boucher. Adenoviral vector infection inhibits human airway epithelial cell proliferation reflecting apoptosis and alteration of the cell cycle. 1994; suppl. 10, p. 222.
    83. Teramoto, S., Johnson, L. G., W. Huang, R.C. Boucher. Effect of adenoviral vector infection on the cell growth in a cystic fibrosis epithelial cell line. 1994; 149(4):A32.
    84. Johnson, L. G., S.E. Boyles, J. Wilson, R.C. Boucher. Correction of raised Na+ absorption and raised Ca2+-mediated Cl- secretion by adenovirus-mediated expression of CFTR in primary human cystic fibrosis airway epithelial cells. 1994; suppl. 10.
    85. Grubb, B.R, R.J. Pickles, H. Ye, R.N. Vick, J.F. Engelhardt, J.M. Wilson, Johnson, L. G., R.C. Boucher. Inefficient gene transfer by adenovirus vector to cystic fibrosis airway epithelia of mice and humans. Nature 371. 1994; 802-806.
    86. Chinet, Th, L.L. Clarke, Johnson, L. G., J. Yankaskas, R.C. Boucher. Regulation of potassium secretion in human nasal epithelial cells in primary culture. 1993; 147(4):A1008.
    87. Olsen, J.C., M.L. Wong-Sun, K.L. Moore, R. Swanstrom, Johnson, L. G., R.C. Boucher. Olsen, J.C., L.G. Johnson, M.L. Wong-Sun, K.L. Moore, R. Swanstrom, and R.C. Boucher. Retrovirus-mediated gene transfer to cystic fibrosis airway epithelial cells: Effect of selectable marker sequences on long-term expression. Nucleic Acids Research 21(3). 1993; 663-669.
    88. Bayle, J.Y., Johnson, L. G., J. St. George, R.C. Boucher, J.C. Olsen. High efficiency gene transfer to primary monkey airway epithelial cells with retrovirus vectors using the GALV receptor. Human Gene Therapy 4. 1993; 161-170.
    89. Johnson, L. G., K.G. Dickman, K.L. Moore, L.J. Mandel, R.C. Boucher. Enhanced Na+ transport in an air-liquid interface culture system. Am. J. Physiol. 264(Lung Cellular and Mol. Physiol. 8). 1993; L560-L565.
    90. Johnson, L. G., R. Pickles, S.E. Boyles, J. Wilson, R.C. Boucher. Effect of CFTR overexpression on Cl- Transport in primary human airway epithelia. 1993; suppl. 9, p. 218.
    91. Johnson, L. G., T.R. Knight, J.C. Olsen, R. Swanstrom, R.C. Boucher. Effect of retrovirus envelope on the efficiency of gene transfer in primary human airway epithelia. 1992; suppl. 8, pg. 265.
    92. Olsen, J.C., Johnson, L. G., M.L. Wong-Sun, K.L. Moore, R. Swanstrom, R.C. Boucher. Long-term expression of a retrovirus-transduced reporter gene in cystic fibrosis airway epithelial. 1992; suppl. 8, p. 265.
    93. Johnson, L. G., J.C. Olsen, B. Sarkadi, K.L. Moore, R. Swanstrom, R.C. Boucher. Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis. Nature Genetics. 1992; 2(1):21-25.
    94. Olsen, J, Johnson, L. G., M.J. Stutts, B. Sarkadi, J.R. Yankaskas, R. Swanstrom, R.C. Boucher. Correction of the apical membrane chloride permeability defect in polarized cystic fibrosis airway epithelia following retroviral-mediated gene transfer. Human Gene Therapy. 1992; 3:253-266.
    95. Bayle, J.-Y, Johnson, L. G., J. Olsen, J. St. George, R. Swanstrom, R.C. Boucher. High efficiency of gene transfer to monkey airway epithelium (MAE) by retroviral infection. 1992; 16F:45.
    96. Ciaccia, A.V., M.J. Stutts, Johnson, L. G., J.C. Olsen, R.C. Boucher, E.M. Price. Topography of the CFTR expressed in Sf9 cells. 1992.
    97. Bayle, J.-Y., Johnson, L. G., J.C. Olsen, J. St. George, R. Swanstrom, R.C. Boucher. Retrovirus-mediated gene transfer to polarized monkey airway epithelium (MAE) in vitro. 1992; suppl. 8, p. 264.
    98. Johnson, L. G., R. C. Boucher, Haas, M. Regulation of Na-K-Cl cotransport in cultured canine airway epithelia. A [3H] bumetanide binding study. Am. J. Physiol. 259: (Cell Physiol. 28). 1990; C557-C569.
    99. Johnson, L. G., P.W. Cheng, R.C. Boucher. Albumin absorption across canine bronchial epithelium. J. Appl. Physiol. 1989; 66(6):2772-2777.
    100. Johnson, L. G. Introduction of therapeutic cDNAs into the lungs of humans and animals. In: Gene Transfer Methods.
    101. Johnson, L. G., R.C. Boucher. Strategies for gene therapy of cystic fibrosis. In: Gene Therapy in Lung Disease.
    102. Johnson, L. G., S.H. Randell, J.C. Olsen. Airway epithelia. In: Lentiviral gene engineering protocols.
    103. Johnson, L. G., R.C. Boucher. Enhanced Na+ transport in an air-liquid interface system. 139(4):A478.
    104. Johnson, L. G. Gene therapy for lung disease: part one.
    105. Johnson, L. G., J.C. Olsen, M. Wong-Sun, J.R. Yankaskas, R.C. Boucher. Optimization of retroviral-mediated gene transfer in transformed and primary human airway epithelial cells.
    106. Martin, S.R., M. Gabor, M. Al-Hamed, R.S. Everett, Johnson, L. G. Attentuation of monocrotaline-induced pulmonary hypertension in rats by luminal AAV gene transfer of prostacyclin synthase.
    107. Johnson, L. G., M.R. Knowles. New therapeutic strategies for CF lung disease: In: Cystic Fibrosis in Adults.
    108. Donohue, J.F, Johnson, L. G. A Review of Home Ventilator-Dependent Patients in North Carolina. 79(2): S5.
    109. Johnson, L. G. Applications of Imaging Techniques to Studies of Epithelial Tight Junctions.
    110. Johnson, L. G. Retroviral Approaches for Gene Therapy of Cystic Fibrosis.
    111. Johnson, L. G., R.C. Boucher. Macromolecular transport across nasal and respiratory epithelia In: Biological Barriers to Protein Delivery. (1993).
    112. Olsen, J.C., Johnson, L. G., J. Yankaskas. Methods for use of retroviral vectors for transfer of the CFTR gene to airway epithelium. In: Methods in Molecular Medicine, Gene Therapy Protocols.
    113. Johnson, L. G., P.W. Cheng, R.C. Boucher. Active transcellular albumin absorption across canine bronchial epithelium. 137(4):221.
    114. Chinet, T., Johnson, L. G., M.J. Stutts, J. Fullton, J.R. Yankaskas, R.C. Boucher. Nasal epithelial cells secrete potassium: a potential role for the apical non-selective cationic channels.
    115. Everett, R.S., M.K. Vanhook, I. Toth, Johnson, L. G., N. Barozzi. Specific modulation of airway tight junctions by a luminal occludin peptide. Mol. Pharmacol. [Epub ahead of print].
    116. Johnson, L. G., R.C. Boucher. Gene therapy for lung disease: molecular and clinical therapeutic issues: In: Lung Biology in Health and Disease: Inhalation Delivery of Therapeutic Peptides and Proteins.
    117. Johnson, L. G., R.C. Boucher. Barriers to efficient airway epithelial gene transfer: lessons from cystic fibrosis. In: Gene Therapy: Therapeutic Mechanisms and Strategies.
    Same Department Expand Description
    Search Department